FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model-Reference-Cited by-同舟云学术

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model

Published:2018-11-12 Issue:2 Volume:144 Page:345-354
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Sow Heng Sheng¹^ORCID,Benonisson Hreinn¹,Breukel Cor¹,Visser Remco²,Verhagen Onno J.H.M.²,Bentlage Arthur E.H.²,Brouwers Conny¹,Claassens Jill W.C.¹,Linssen Margot M.¹,Camps Marcel³,van Hall Thorbald⁴,Ossendorp Ferry³,Fransen Marieke F.³,Vidarsson Gestur²,Verbeek J. Sjef¹

Affiliation:

1. Department of Human Genetics; Leiden University Medical Center; Leiden the Netherlands

2. Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre; University of Amsterdam; Amsterdam the Netherlands

3. Department of Immunohematology; Leiden University Medical Center; Leiden the Netherlands

4. Department of Medical Oncology; Leiden University Medical Center; Leiden the Netherlands

Funder

KWF Kankerbestrijding

European Union's Seventh Framework Programme

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.31899/fullpdf

Reference41 articles.